Gunderson Dettmer Successfully Navigates BillionToOne's $273.1 Million IPO Amidst Market Complexities

Gunderson Dettmer Successfully Supports BillionToOne's IPO

On November 6, 2025, BillionToOne, Inc., a recognized player in the field of molecular diagnostics, made headlines as it launched an upsized Initial Public Offering (IPO) that raised approximately $273.1 million. Leading the charge in representing this milestone was Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, a renowned legal firm specializing in technology and life sciences transactions.

The IPO itself consisted of 4.6 million shares of Class A common stock, priced at $60 per share. Trading commenced on the Nasdaq Global Select Market on the same day, and the offering is anticipated to wrap up on November 7, 2025. This public offering marks a significant leap for BillionToOne, whose goal has always been to democratize access to advanced genetic testing, empowering individuals with crucial health information.

Gunderson Dettmer’s involvement with BillionToOne spans several crucial financing rounds, showcasing their pivotal role in the company’s evolution from inception through to its public market debut. Their counsel navigated the complexities of a changing capital markets landscape, including challenges presented by the current government shutdown, providing strategic support throughout the process.

A suite of prestigious financial institutions joined the effort; J.P. Morgan, Piper Sandler, Jefferies, and William Blair acted as joint book-running managers, while Stifel, Wells Fargo Securities, and BTIG also contributed their expertise to the offering.

The Gunderson team at the forefront of this transaction included corporate partner Nick Harley, alongside partners Andrew Thorpe and Alexa Belonick, who specialize in public companies and offerings. Supporting them were associates Elena Vespoli, Michael Tiab, Jenny Whalen-Ball, and Megan Wiener, in addition to executive compensation partner Michael Richman and associate Erik Ward, not to mention the invaluable assistance from senior paralegals Scott Paraker and Doug Ikegami.

Understanding the significance of accessibility in genetic testing, BillionToOne’s mission aligns with evolving health standards and consumer expectations in a world increasingly focused on personalization in care. The IPO is a signal not only of the company’s growth but also of the increasing importance placed on genetic testing technologies in enhancing public health initiatives.

Gunderson Dettmer aims to provide unmatched legal expertise tailored for the innovation economy, and their work with BillionToOne underscores their capabilities in supporting cutting-edge firms through various stages of growth. With their guidance, BillionToOne now stands poised to advance its mission of making advanced diagnostics available to all.

As the market continues to evolve, the successful launch of this IPO sets a powerful precedent. It reflects a robust belief in the future of biotechnology and molecular diagnostics, paving the way for similar ventures aiming to transform healthcare accessibility on a larger scale. This event is not just a financial milestone for BillionToOne but also a beacon of hope, signifying a future where essential health information is at everyone's fingertips.

Keep an eye on the developments from this high-profile IPO as BillionToOne transitions into the public arena under the knowledgeable counsel of Gunderson Dettmer.